Who is sponsoring NCT04584242?

NCT04584242 is sponsored by Yonsei University.

What drugs are being tested in NCT04584242?

Interventions in NCT04584242: gluconon tab 15mg, suganon tab 5mg.

Is NCT04584242 still recruiting?

NCT04584242 is currently status unknown. Last updated 7 October 2020.

Last reviewed 2020-10-07 · How we verify

NCT04584242

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective, Multicenter, Randomized, and Comparative Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes

Status unknown Phase 4 Last updated 7 October 2020

What this trial tests

Phase 4 trial testing gluconon tab 15mg in Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes in 40 participants. Status unknown.

Timeline

3 September 2020

Primary endpoint
1 May 2022

1 May 2022

Quick facts

Lead sponsor	Yonsei University
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	3 September 2020
Primary completion	1 May 2022
Estimated completion	1 May 2022
Sites	4 locations across South Korea

Drugs / interventions tested

gluconon tab 15mg — full drug profile →
suganon tab 5mg — full drug profile →

Conditions studied

Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes — all drugs for Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes →

Sponsor

Yonsei University

Who can join

Adults 20 to 80, any sex, with Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Changes from baseline LSM (Liver Stiffness measurement) at week 24 (±7days)
Time frame: Baseline
Changes in the Liver Stiffness measurement after 24 weeks (±7days) compared to Baseline within and between arms
Changes from baseline LSM (Liver Stiffness measurement) at week 24 (±7days)
Time frame: Baseline to 24 weeks (±7days)
Changes in the Liver Stiffness measurement after 24 weeks (±7days) compared to Baseline within and between arms

Sponsor's own description

The clinical study determines the effect of Evogliptin in patients with type 2 diabetes mellitus and chronic hepatitis B to confirm the improvement of hepatic fibrosis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Decoding organ fibrosis: mechanistic insights and emerging therapeutic strategies.
Chen X, Zhang J, Guo L, Wu C, et al · · 2026 · cited 2× · PMID 41786685 · DOI 10.1038/s41392-025-02532-0

Verify or expand the search:

Other Yonsei University trials

Trials by the same sponsor.

NCT07547592 — Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma · Phase 2 · not yet recruiting
NCT07524101 — Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD · NA · not yet recruiting
NCT07506629 — Adductor Canal Block Methods in Bilateral Total Knee Arthroplasty · NA · not yet recruiting
NCT07515716 — Effects of High Flow Humidified Oxygen on Umbilical Artery Acid-base Balance in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
NCT07507188 — Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04584242 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yonsei University
Last refreshed: 7 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04584242.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing